What peer‑reviewed research has Dr. Ania Jastreboff published on GLP‑1 medications and neural responses to food cues?
Executive summary
Dr. Ania M. Jastreboff has authored peer‑reviewed reviews and clinical trial publications that situate GLP‑1 receptor agonists within modern obesity therapeutics and has led high‑profile clinical trials of GLP‑1–based and multi‑agonist drugs, while her doctoral work and listed outputs indicate a research track record in neuroimaging of food cues and stress—although the public record in the supplied reporting does not enumerate a single, standalone peer‑reviewed fMRI/PET paper by name linking GLP‑1 drugs to neural food‑cue responses [1] [2] [3].
1. Published reviews that frame GLP‑1 biology and brain mechanisms
Dr. Jastreboff coauthored a major review, “New Frontiers in Obesity Treatment: GLP‑1 and Nascent Nutrient‑Stimulated Hormone‑Based Therapeutics,” published in Annual Review of Medicine, which synthesizes the neurobiology of obesity, the mechanism of GLP‑1 receptor agonists (GLP‑1 RAs), and the prospects for combination or multi‑hormone therapeutics—the review explicitly links expanding neurobiological understanding to the therapeutic promise of GLP‑1 RAs [1].
2. High‑impact clinical trial authorship on GLP‑1/GIP agents
She served as lead or senior author on high‑visibility, peer‑reviewed clinical trial publications involving GLP‑1–related therapeutics, notably the SURMOUNT‑1 trial of tirzepatide (a dual GIP/GLP‑1 receptor agonist) published in the New England Journal of Medicine, which established tirzepatide’s substantial weight‑loss effects and placed GLP‑1/GIP combination biology at the center of contemporary obesity treatment debates [2] [3].
3. Participation in phase‑2/3 trials and multi‑agonist research
Beyond SURMOUNT‑1, the record shows Jastreboff as an investigator or author on several phase‑2 and phase‑3 studies of next‑generation incretin and multi‑agonist agents (retatrutide, maridebart/mariTide, amycretin and others), with her name appearing on clinical trial reports, abstracts and NEJM correspondence that describe GLP‑1/GIP/glucagon multi‑agonists and once‑monthly formulations—evidence of peer‑reviewed clinical contributions to how GLP‑1 biology is being translated into new therapeutics [4] [5] [6] [7].
4. Neuroimaging, doctoral work, and the gap in explicit peer‑reviewed fMRI papers linking GLP‑1 drugs to food‑cue responses
Her PhD dissertation focused on “Neural Response to Food Cues and Stress in Individuals with Obesity,” and institutional biographies and profiles state she has conducted neuroimaging studies (fMRI and PET) examining the neurobiology underlying obesity and mechanisms of anti‑obesity drugs [3] [8]. However, the supplied reporting does not provide the citation of a specific, standalone peer‑reviewed fMRI or PET paper by Jastreboff that experimentally tests how GLP‑1 medications alter neural responses to food cues; therefore the public material reviewed supports that she has neuroimaging expertise and related publications, but does not allow definitive attribution of a particular peer‑reviewed neuroimaging article that directly measures neural responses to food cues before/after GLP‑1 therapy [3] [5].
5. Related mechanistic and translational publications that imply brain‑targeted effects
Coauthored work listed in databases and index entries (including a Cell Metabolism article and other collaborative pieces) address GLP‑1’s interactions with central and neurovascular systems and show her contribution to mechanistic literature that situates GLP‑1 signaling in brain–body pathways; such papers imply a translational bridge from neural response studies to pharmacology even if an explicit fMRI trial of GLP‑1 drugs and food cues is not named in the provided sources [6] [1].
6. Conflicts of interest, clinical roles and how that shapes interpretation
Public profiles note that Jastreboff serves on industry scientific advisory boards (Novo Nordisk, Eli Lilly) and that industry funded many of the clinical trials she worked on; this is relevant context when weighing intervention trials and therapeutic advocacy in her peer‑reviewed portfolio [9]. The sources also emphasize her leadership at Yale’s obesity research center and frequent media/scientific commentary roles, which amplify her translational and policy influence [8] [10].
Conclusion: the supplied reporting documents Dr. Jastreboff’s peer‑reviewed contributions to review literature on GLP‑1 therapeutics and to multiple high‑profile clinical trials (including NEJM publications), and it documents her doctoral focus and ongoing neuroimaging work on neural food‑cue responses; however, the materials provided do not list a specific peer‑reviewed fMRI or PET paper by name that experimentally demonstrates how GLP‑1 medications alter neural responses to food cues, so a conservative reading is that she has the expertise and has contributed to mechanistic and clinical literature connecting GLP‑1 biology and brain function, while the precise neuroimaging‑with‑GLP‑1 paper are not explicitly cited in the supplied sources [1] [2] [3] [6].